HomeLoginSite MapContact Us
Click to submit search
  Donate Now!

SMA ResearchFSMA CommunitySMA Fundraising
Newcompbanner
Fundraising Events
Registry

Connect with Families of SMA:

FacebookBanner

TwitterBanner

YouTubeBanner

 


Display a Printer Friendly Version This Page

Trophos Increases Focus on Neuroprotection Including Spinal Muscular Atrophy.
December 29, 2008.

TRO19622: development in Spinal Muscular Atrophy (SMA), an orphan neurodegenerative disorder, continues following successful phase Ib study in SMA patients in France. 

The company will continue its development program in SMA with TRO19622 following a phase Ib PK and tolerability study in SMA patients ranging from 6-25 years old in France, which demonstrated good tolerability and established the pharmacokinetic characteristics of the molecule in children. Discussions are ongoing with the EMEA regarding appropriate trial design to demonstrate efficacy and allow registration in this indication.  This program has received financial support from the Association Française contre les Myopathies (AFM).

Read the whole press release here.

 

Click here for the Trophos web site.


 

Site Map Contact Us Privacy Policy Legal Terms & Conditions